Real World CE: Accredited Clinical Curriculum verified 1.5 AMA PRA Category 1 Credits™
REAL WORLD CE Featuring: REAL WORLD CASE
Lab Background
Interactive Clinical Simulation

Manage the
Unmanageable CMV

Master the transition from failed Valganciclovir therapy to genotypic-guided rescue. A complete hands-on module for transplant professionals.

Start Simulation play_arrow

Phase 01: Sarah's Case

Follow Sarah, a 48-year-old kidney recipient, through a refractory crisis. Your decisions determine graft survival.

Sarah

Sarah Jenkins

48y Kidney Recipient

Creatinine

1.4 mg/dL

Viral Load

35,000

// CLINICAL NOTE

"Sarah presents with fatigue and leukopenia 1 month post-prophylaxis. Day 14 of therapy."

clinical_notes Decision Point 01

Therapeutic Failure?

Sarah has been on Valganciclovir 900mg BID for 14 days. Her viral load has only dropped from 38k to 35k IU/mL (< 1 log10 reduction). What is the standard next action?

deployed_code

Interactive Lab 02

The Mutation Landscape

Interact with the 3D virion to identify the two major structural targets of CMV antiviral therapy.

Molecular Diagnosis Bench

Simulate the DNA extraction process to reveal the genotype.

Sarah's Plasma
colorize
Lysis Buffer

Click the pipette icon to transfer plasma and start extraction.

Viral Kinetics Simulation

Adjust the efficacy of the first-line therapy to model the Breakthrough Rebound. This "U-shaped" curve is a clinical red flag for biological resistance.

90%
Tip: Lower efficacy (due to mutation) allows the red line (Resistant Strain) to outcompete the blue line (Wild Type).

Global Mastery Assessment

Complete all 15 questions to claim your credits.

01 / 15